Petros Pharmaceuticals announces transition from Nasdaq to OTC Markets
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 21 2025
0mins
Should l Buy ?
Delisting from Nasdaq: Petros Pharmaceuticals has received a letter from Nasdaq indicating that its common stock will be suspended and delisted from the exchange starting May 22, 2025.
Transition to OTC Markets: Following the suspension, Petros' securities are expected to begin trading on the OTC Markets under the ticker "PTPI".
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
